Communiqués de presse Archive - Page 17 of 19 - Ose Immunotherapeutics - Société de biotechnologie intégrée qui développe des immunothérapies innovantes

OSE Immunotherapeutics Presented Positive Correlation Between Neoepitope Response and Increased Survival for NSCLC Patients Treated with Tedopi®

OSE Immunotherapeutics Announces Licensing Deal for Neoepitope Combination Tedopi® in Korea

OSE Immunotherapeutics Presents New Preclinical Data on its Novel Bispecific Checkpoint Inhibitor

OSE Immunotherapeutics Receives a Milestone Payment of €5.4 Million From Bpifrance

OSE Immunotherapeutics Reports First Half 2019 Results and Provides a Corporate Update

OSE Immunotherapeutics Receives New European Patent Protection Through 2037 for OSE-703

OSE Immunotherapeutics Receives a Grant from the French National Research Agency

First Publication from OSE Immunotherapeutics on the Role of SIRPα in the Induction and Maintenance of Immune Tolerance

OSE Immunotherapeutics Receives Special Recognition for European Growth

OSE Immunotherapeutics Announces Results of 2019 Annual Shareholder Meeting

Précédent
1
…
14
15
16
17
18
19
Suivant